Clinical Roundup ImmunityBio announces positive phase II data for Anktiva + checkpoint inhibitors in lung cancer, opens phase III trial ImmunityBio Inc. announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer being treated with checkpoint inhibitors. September 13, 2024Vol.50 No.34
